文献速递炎症性肠病消化内镜

肠道超声在克罗恩病紧密监测中的应用:多中心前瞻性研究

Use of Intestinal Ultrasound in a Tight Monitoring Approach in Crohn's Disease: A Multicenter Prospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-04-15

BACKGROUND & AIMS: Intestinal ultrasound (IUS) is increasingly used to monitor Crohn's disease (CD) activity, yet its optimal role in tight monitoring strategies remains unclear.…

要点

  • 第14周IBUS-SAS <56.6可独立预测第54周内镜缓解(OR 19.0,95%CI 1.91-189.6)。
  • 第14周IBUS-SAS <56.6预测内镜缓解的AUC为0.861,肠壁厚度<2.9 mm的AUC为0.802。
  • 第54周内镜、肠道超声和磁共振小肠造影缓解率分别为40%、42%和33%。

核心结论

  • 早期肠道超声评估可无创预测抗TNFα治疗1年后的内镜缓解,支持将其整合进克罗恩病紧密监测方案。

研究设计与样本

  • 基线和第54周行回结肠镜和磁共振小肠造影,基线、第14、30、54周行生物标志物和肠道超声检查。

主要发现

  • 治疗1年后,40%、42%和33%的患者分别达到内镜、肠道超声和磁共振小肠造影缓解。
  • 达到内镜缓解的患者在所有时间点的肠壁厚度中位数和IBUS-SAS评分均显著更低。
  • 第14周预测内镜缓解的最佳指标为IBUS-SAS <56.6(AUC=0.861)和肠壁厚度<2.9 mm(AUC=0.802)。

关键数值与推荐

  • 内镜缓解定义为节段性克罗恩病简化内镜评分(SES-CD)等于0。
  • 肠道超声缓解定义为肠壁厚度、分层、血管化和肠系膜脂肪恢复正常。
  • IBUS-SAS检测内镜缓解的最佳截断值为56.6。

临床怎么用

  • 可在抗TNFα治疗早期(如第14周)采用肠道超声进行紧密监测,以预测1年内镜缓解。
  • IBUS-SAS <56.6提示治疗反应良好,可作为无创替代内镜和影像的实时评估工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Intestinal ultrasound (IUS) is increasingly used to monitor Crohn's disease (CD) activity, yet its optimal role in tight monitoring strategies remains unclear. We aimed to assess the predictive role of ultrasonographic parameters in determining endoscopic remission (ER) after one year of anti-tumor necrosis factor α, and the correlation of IUS parameters with other outcomes longitudinally. METHODS: This was a multicentric prospective longitudinal study enrolling adult patients with active CD starting anti-tumor necrosis factor α. Biomarkers and IUS were performed at baseline, week (W)14, W30, and W54; ileocolonoscopy and magnetic resonance enterography were performed at baseline and W54. The primary outcome was the predictive value of IUS remission (normalization of bowel wall thickness [BWT], stratification, vascularization, and mesenteric fat) for ER at W54 (segmental Simple Endoscopic Score for Crohn's Disease = 0). The International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) optimal cut point to detect ER was identified using receiver operating characteristic analysis. RESULTS: Sixty-three patients were included, of whom 57 were followed until W54. After 1 year of therapy, 40%, 42%, and 33% achieved endoscopic, IUS, and magnetic resonance enterography remission, respectively. Patients with ER had a significantly lower median BWT and IBUS-SAS score at all time points. The best predictors for ER were IBUS-SAS <56.6 (area under the curve = 0.861) and BWT <2.9 mm (area under the curve = 0.802) at W14. On multivariable analysis, IBUS-SAS <56.6 at W14 was the only independent predictor for ER (odds ratio, 19.0; 95% confidence interval, 1.91-189.6; P = .012). CONCLUSIONS: Early IUS evaluation can noninvasively predict treatment outcomes, supporting its integration into tight monitoring protocols for CD. IUS offers a real-time, cost-effective alternative to endoscopy and imaging, potentially enabling timely therapy optimization to improve patient management.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Palmela C, Revés J, Frias-Gomes C, et al. Use of Intestinal Ultrasound in a Tight Monitoring Approach in Crohn's Disease: A Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2026. PMID: 41997335. doi:10.1016/j.cgh.2026.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。